What is Compounded Tirzepatide?
Tirzepatide is a dual-action medication that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors — making it one of the most powerful weight loss medications currently available. By targeting two separate hormonal pathways simultaneously, it delivers stronger appetite suppression, greater improvements in blood sugar control, and more significant fat loss compared to GLP-1 therapy alone.
Like Semaglutide, Compounded Tirzepatide is administered as a once-weekly subcutaneous injection with a gradual dose escalation protocol. Clinical trials (SURMOUNT-1) demonstrated average weight loss of 20–22% of total body weight over 72 weeks — among the highest of any approved weight loss therapy.
At HydraSpa, Tirzepatide is prescribed and supervised by our clinical team as part of a comprehensive, personalized weight management program that includes ongoing monitoring, dose adjustments, and lifestyle support.
What patients typically experience
- Powerful dual-pathway appetite suppression (GLP-1 + GIP)
- Average 20–22% total body weight loss in clinical trials
- Superior blood sugar control — significant HbA1c reduction
- Improved insulin sensitivity and metabolic function
- Reduced visceral (abdominal) fat
- Lower cardiovascular risk markers
- Reduced cravings for high-calorie foods
- Clinically supervised titration for comfort and safety
Who is a good candidate?
- Adults with a BMI of 27 or higher with at least one weight-related condition
- Adults with a BMI of 30 or higher
- Patients with type 2 diabetes or insulin resistance who would benefit from dual hormonal support
- Those who have tried Semaglutide and are looking for a more potent option
- Individuals seeking the most clinically advanced GLP-1/GIP combination therapy available
- Patients without a personal or family history of medullary thyroid carcinoma or MEN2 syndrome
Common questions
- How is Compounded Tirzepatide different from brand-name Mounjaro or Zepbound?
- Compounded Tirzepatide contains the same active ingredient as Mounjaro and Zepbound but is prepared by a licensed compounding pharmacy. It is prescribed and supervised by our clinical team and is often more accessible and cost-effective than brand-name alternatives.
- How does Tirzepatide compare to Semaglutide?
- Tirzepatide activates two hormonal receptors (GLP-1 and GIP) while Semaglutide activates one (GLP-1). Clinical trials show Tirzepatide produces greater average weight loss — 20–22% vs. 15–17% for Semaglutide. Our clinical team can help you determine which is the better fit for your health history and goals.
- How quickly will I see results?
- Most patients notice reduced appetite within the first 1–2 weeks. Measurable weight loss typically begins within the first month and accelerates as dosing is titrated upward. Clinical trial results show 20–22% total body weight loss over 72 weeks on average.
- What are the most common side effects?
- The most common side effects are gastrointestinal — nausea, mild bloating, or reduced appetite — particularly during the early dose escalation phase. These typically resolve as your body adjusts. Our clinical team monitors your response and adjusts dosing as needed.
- Is a consultation required before starting?
- Yes. All patients complete a clinical consultation and health history review before beginning any GLP-1/GIP program. This ensures the medication is appropriate for you and that your starting dose and titration schedule are personalized to your needs.
Not sure if Tirzepatide is right for you?
Semaglutide is an excellent option for many patients and may be the right starting point. Our clinical team will review your health history and help you choose the program that fits your goals.
HydraSpa Integrative Health
San Antonio, TX
Mon – Fri: 9am – 5pm | Sat: By appointment
Book Your Consultation